Researchers claim a combination of high sodium and low potassium is worse for heart health than either factor alone.
A new study linking sodium and potassium intake levels to cardiovascular disease (CVD) sheds new light on our understanding of CVD risk reduction. The study is published in the journal Archives of Internal Medicine.
Researchers from Harvard University, Emory University, and the Centers for Disease Control and Prevention examined data available from 12,267 subjects who participated in the Third National Health and Nutrition Examination Survey (NHANES III). Subjects participated in physical examinations and interviews for diet and lifestyle factors. All subjects were at least 20 years of age and had no history of CVD. Subjects participated in follow-up for an average of 14.8 years.
During the study, 36% of subjects died from CVD.
After adjusting for sex, race, body mass index, and other variables, higher sodium intake was associated with higher CVD mortality rates and higher potassium rates were associated with lower CVD morality rates.
But the combination of high sodium and low potassium created even greater CVD risk than either factor alone. The highest quartile of sodium-to-potassium ratio came with a 46% increased risk of CVD compared to the lowest quartile.
“High sodium levels induce increased blood pressure and hypertension by stiffening endothelial cells, thickening and narrowing resistance arteries, and blocking nitric oxide synthesis, whereas high potassium levels can counteract these effects by activating nitric oxide release,” wrote the study’s author. “The opposite biological effects of sodium and potassium may explain stronger associations of sodium-potassium ratio with CVD mortality than either sodium or potassium intake alone.”
The author noted that previous research on a link between the sodium-potassium ratio and CVD risk has been inconsistent, but this could be due to poorly designed studies.
“Public health recommendations should emphasize simultaneous reduction in sodium intake and increase in potassium intake,” concluded the author.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.